Negative prognostic impact of regulatory T cell infiltration in surgically resected esophageal cancer post-radiochemotherapy

Oncotarget

Volumn 6, Issue 25, 2015, Pages 20840-20850

  Vacchelli, Erika ^a,b,c,d,e   Semeraro, Michaela ^a,b,f   Enot, David P ^a,b,c   Chaba, Kariman ^a,b,c,d   Colame, Vichnou Poirier ^a,b,f   Dartigues, Peggy ^a   Perier, Aurelie ^a,b,f   Villa, Irene ^a   Rusakiewicz, Sylvie ^a,b,f   Gronnier, Caroline ^g,h   Goéré, Diane ^a   Mariette, Christophe ^g,h   Zitvogel, Laurence ^a,b,f,i   Kroemer, Guido ^a,b,c,d,e,j  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSERM   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f Center of Clinical Investigations in Biotherapies of Cancer (CICBT)   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h UNIV LILLE   (France)

ⁱ UNIVERSITÉ PARIS SACLAY   (France)

^j HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

more..

Author keywords

Apoptosis; ATG16L1; Autophagy; Immunogenic cell death; Pattern recognition receptor

Indexed keywords

CD8 ANTIGEN; CISPLATIN; FLUOROURACIL; LIGAND GATED ION CHANNEL; OXALIPLATIN; PURINERGIC P2X RECEPTOR; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; P2RX7 PROTEIN, HUMAN; PURINERGIC P2X7 RECEPTOR; TLR4 PROTEIN, HUMAN;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CELL DENSITY; CHEMORADIOTHERAPY; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; GENE; HUMAN; HUMAN TISSUE; LOSS OF FUNCTION MUTATION; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; P2RX7 GENE; REGULATORY T LYMPHOCYTE; TLR4 GENE; TREATMENT RESPONSE; ALLELE; APOPTOSIS; CD8+ T LYMPHOCYTE; COHORT ANALYSIS; CYTOLOGY; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION; GENOTYPE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; PROCEDURES; PROGNOSIS; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

ALLELES; APOPTOSIS; CD8-POSITIVE T-LYMPHOCYTES; CHEMORADIOTHERAPY; COHORT STUDIES; ESOPHAGEAL NEOPLASMS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; PROGNOSIS; RECEPTORS, PURINERGIC P2X7; T-LYMPHOCYTES, REGULATORY; TOLL-LIKE RECEPTOR 4; TREATMENT OUTCOME;

EID: 84940778944     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4428     Document Type: Article

References (42)

1. Hanahan, D. and R.A. Weinberg, Hallmarks of cancer: the next generation. Cell, 2011. 144: p. 646-74.
2. Schreiber, R.D., L.J. Old, and M.J. Smyth, Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science, 2011. 331: p. 1565-70.
3. Zitvogel, L., O. Kepp, and G. Kroemer, Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol, 2011. 8: p. 151-60.
4. Galluzzi, L., et al., The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov, 2012. 11: p. 215-33.
5. Zitvogel, L., et al., Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity, 2013. 39: p. 74-88.
6. Denkert, C., et al., Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol, 2010. 28: p. 105-13.
7. Loi, S., et al., Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol, 2013. 31: p. 860-7.
8. Issa-Nummer, Y., et al., Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer-a substudy of the neoadjuvant GeparQuinto trial. PLoS One, 2013. 8: p. e79775.
9. Denkert, C., et al., Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers. J Clin Oncol, 2014.
10. Ladoire, S., et al., In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol, 2011. 224: p. 389-400.
11. Senovilla, L., et al., An immunosurveillance mechanism controls cancer cell ploidy. Science, 2012. 337: p. 1678-84.
12. Apetoh, L., et al., Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med, 2007. 13: p. 1050-9.
13. Ghiringhelli, F., et al., Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med, 2009. 15: p. 1170-8.
14. Sistigu, A., et al., Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med, 2014. 20: p. 1301-9.
15. Vacchelli, E., et al., Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer. Oncoimmunology, 2012. 1: p. 271-278.
16. Tesniere, A., et al., Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene, 2010. 29: p. 482-91.
17. Schumacher, K., et al., Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res, 2001. 61: p. 3932-6.
18. Cho, Y., et al., CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res, 2003. 63: p. 1555-9.
19. Ashida, A., et al., Expression profiling of esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy: clinical implications. Int J Oncol, 2006. 28: p. 1345-52.
20. Lv, L., et al., The accumulation and prognosis value of tumor infiltrating IL-17 producing cells in esophageal squamous cell carcinoma. PLoS One, 2011. 6: p. e18219.
21. Chen, L.J., et al., B7-H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma. Cancer Immunol Immunother, 2011. 60: p. 1047-55.
22. Dutta, S., et al., The relationship between tumour necrosis, tumour proliferation, local and systemic inflammation, microvessel density and survival in patients undergoing potentially curative resection of oesophageal adenocarcinoma. Br J Cancer, 2012. 106: p. 702-10.
23. Ichihara, F., et al., Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res, 2003. 9: p. 4404-8.
24. Huang, C. and Z.X. Fu, Localization of IL-17+Foxp3+ T cells in esophageal cancer. Immunol Invest, 2011. 40: p. 400-12.
25. Gabitass, R.F., et al., Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother, 2011. 60: p. 1419-30.
26. Wang, G., et al., FOXP3 expression in esophageal cancer cells is associated with poor prognosis in esophageal cancer. Hepatogastroenterology, 2012. 59: p. 2186-91.
27. Kono, K., et al., CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother, 2006. 55: p. 1064-71.
28. Xue, L., et al., Expression of FOXP3 in esophageal squamous cell carcinoma relating to the clinical data. Dis Esophagus, 2010. 23: p. 340-6.
29. Zingg, U., et al., Tumour-infiltrating lymphocytes and survival in patients with adenocarcinoma of the oesophagus. Eur J Surg Oncol, 2010. 36: p. 670-7.
30. Wang, G., et al., Correlation between the CD4+CD25high regulatory T cells and the outcome of chemotherapy in advanced esophageal carcinoma. Hepatogastroenterology, 2013. 60: p. 704-8.
31. Mandard, A.M., et al., Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer, 1994. 73: p. 2680-6.
32. Hofman, P., et al., Genetic and Pharmacological Inactivation of the Purinergic P2RX7 Receptor Dampens Inflammation but Increases Tumor Incidence in a Mouse Model of Colitis-Associated Cancer. Cancer Res, 2015.
33. Liu, Q., et al., Down-regulation of HLA class I antigen-processing machinery components in esophageal squamous cell carcinomas: association with disease progression. Scand J Gastroenterol, 2009. 44: p. 960-9.
34. Tsuchikawa, T., et al., Association of CD8+ T cell infiltration in oesophageal carcinoma lesions with human leucocyte antigen (HLA) class I antigen expression and survival. Clin Exp Immunol, 2011. 164: p. 50-6.
35. Tsuchikawa, T., et al., The immunological impact of neoadjuvant chemotherapy on the tumor microenvironment of esophageal squamous cell carcinoma. Ann Surg Oncol, 2012. 19: p. 1713-9.
36. Izawa, S., et al., Increased prevalence of tumor-infiltrating regulatory T cells is closely related to their lower sensitivity to H2O2-induced apoptosis in gastric and esophageal cancer. Cancer Immunol Immunother, 2013. 62: p. 161-70.
37. Maruyama, T., et al., CCL17 and CCL22 chemokines within tumor microenvironment are related to infiltration of regulatory T cells in esophageal squamous cell carcinoma. Dis Esophagus, 2010. 23: p. 422-9.
38. Zhu, X.M., et al., High mobility group box-1 protein regulate immunosuppression of regulatory T cells through toll-like receptor 4. Cytokine, 2011. 54: p. 296-304.
39. Rao, S., et al., A dual role for autophagy in a murine model of lung cancer. Nat Commun, 2014. 5: p. 3056.
40. Team, R.D.C., R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/. 2014.
41. Heinze, G., A comparative investigation of methods for logistic regression with separated or nearly separated data. Stat Med, 2006. 25: p. 4216-26.
42. Hothorn, T. and B. Lausen, On the exact distribution of maximally selected rank statistics. Computational Statistics & Data Analysis, 2003. 43: p. 121-137.